Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Monoclonal Gammopathy of Undetermined Significance

Paraproteinemias

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Hypergammaglobulinemia

All Drugs and Chemicals

Myeloma Proteins

Paraproteins

Multiple myeloma (MM) is a hematologic malignant tumor characterized by abnormally cloned plasma cells in bone marrow, whose growth can lead to destructive bone injury, acute kidney injury, anemia, and hypercalcemia.

Individuals in good health without obvious disease and with normal physical examination report; Avoid people who have not suffered from major chronic diseases in recent years, such as hypertension, diabetes, chronic kidney disease, etc; controls were appropriately selected that matched cases for age and sex.

Observational studies, no intervention

Nianyi Zeng

Hongwei Zhou, Professor

To provide a comprehensive MALDI-TOF mass spectrometry method for detecting, characterizing, and quantifying M-protein, and to track M-protein in a very sensitive and specific manner during patient treatment, providing a more precise test for diagnosing disease and monitoring patient response to treatment.

M-protein is a serum biomarker directly related to clonal plasma cell load in Multiple myeloma (MM) patients and can be used as a diagnostic marker to make out disease and a quantitative marker to track disease progression and response to treatment. Identification, typing and quantification of M-proteins are useful for initial diagnosis of disease, risk stratification and monitoring of response to treatment. Although the determination of M-protein can be used as an auxiliary diagnosis of multiple myeloma, the early diagnosis and risk assessment of MM still lack convenient and effective tools for large-scale screening. In recent years, the use of matter-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for proteomic analysis of complex biological mixtures has attracted extensive attention, and has become one of the most promising methods for the detection of m proteins. In this study, we screened the population by MALDI mass spectrometry in order to detect low level circulating M-protein by a faster and more sensitive method.

Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis

M-protein in urine and serum detected using MALDI-TOF Mass Spectrometry

National Natural Science Foundation of China

Zhujiang Hospital

Professor

Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

Digestive System Diseases

Diabetes Mellitus, Type 2

Diabetes Mellitus

Atherosclerosis

Inflammatory Bowel Diseases

Intestinal Diseases

Gastrointestinal Diseases

Metabolic Diseases

Glucose Metabolism Disorders

Endocrine System Diseases

Gastroenteritis

Arteriosclerosis

Arterial Occlusive Diseases

Acetylmuramyl-Alanyl-Isoglutamine

Jie Gao, PHD

Zhou Hongwei, Professor

Hongwei Zhou, professor

Nucleotide-binding oligomerization domain 2 (Nod2) signaling is critical for human health.To figure out the clinical relevance of NOD2 ligands, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ).

Previous studies have shown that NOD2 gene mutants were associated with the Crohn's disease (CD), colorectal cancer (CRC) and many other diseases, suggesting the critical role of NOD2 signaling in human physiology and pathogenethesis. However, whether decreased NOD2 ligands also contributed to these diseases is unknown. In this study, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ). For each of the patient, a sex- and age- matched control were chosen. Both the targeted metabolomics (LC-MS-MS methods) and NOD2-transfected cells co-expressing NF-κB luciferase reporters were used to test NOD2 ligands in the fecal and plasma samples.

Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases

A Bacterial Bi-functional Peptidoglycan Hydrolase Sheds NOD2 Ligands to Regulate Gut Homeostasis

detected using targeted metabolomics (LC-MS-MS methods) and NOD2-transfected cells co-expressing NF-κB luciferase reporters

Proffessor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis	NCT05686447	Monoclonal Gamm... Multiple Myelom... M-protein	Observational s...	-	Zhujiang Hospital
Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases	NCT04924686	Colorectal Canc... Inflammatory Bo... Atherosclerotic... Type2 Diabetes ...	Observational s...	18 Years - 70 Years	Zhujiang Hospital

Spots Global Cancer Trial Database for observational studies, no intervention